Physician profile
Brent Yoder
NPI 1497831184
$2,211.33
in general payments reported to CMS, 2019-2025
24 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.02 · 2022: $635 · 2023: $605 · 2024: $516 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.16 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $273.42 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $140.24 | 2021-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $136.70 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $94.94 | 2024 | Nuzyra |
| Shield Therapeutics INC | $77.94 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $77.85 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $73.32 | 2022-2025 | Farxiga |
| Pfizer INC. | $72.99 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $72.10 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.51 | 2022-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $68.85 | 2022-2023 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $59.52 | 2022-2023 | |
| Lundbeck LLC | $59.15 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $42.74 | 2023 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.49 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $31.30 | 2022-2024 | Eliquis |
| Glaxosmithkline, LLC. | $26.34 | 2022-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $22.37 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.02 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.55 | 2023 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.23 | 2025 | Caplyta |
| Dexcom, INC. | $12.86 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.